Annual Forum on Field-Based Dissemination of Scientific Information
Featured Conference The Definitive Annual Forum on Field-Based Dissemination of Scientific Information May 12 -...
FDA Drug Watch Site Guidelines
As reported in today's Wall Street Journal ("FDA Issues Guidelines For 'Drug Watch' Site, Details on Oversight Board") , the FDA issued a Gudiance...
Get a Load of Those Gams!
"A group of Congressmen publicly released a set of pharma company sales documents yesterday. The House Committee on Government Reform published the Merck documents,...
The Two Bobs: Enzyte vs. Viagra
I read -- with sadness, I must admit -- that the offices of Berkeley Premium Nutraceuticals, the company that brought us Enzyte, the "natural...
Innovative Marketing for Innovative Drugs
According to an article in today's Wall Street Journal, "Pfizer Inc., the maker of Lipitor, blames the German health ministry for a significant drop...
A Good Time Was Had by All
Nearly 70 people showed up at the Second Annual Networking Dinner Reception on May 18, 2005, in Metuchen, New Jersey. Attendees spent several hours networking, enjoying dinner, and brain-storming ideas about how to improve the Network and the services offered.
Is Pharma Marketing a Lot of BS?
All marketers are bullshitters! What are some noteworthy examples of pharmaceutical marketing bullshit? How does marketing bullshit hurt the industry?
Return on CME: Are Pharma Companies Getting Desired Outcomes?
This article summarizes a presentation by Sharyn Lee, CEO and cofounder of Medical Educational Broadcast Network (MEBN), a medical education communications and publishing company, who spoke on outcomes-based CME and the importance of selecting the best assessment tool at a recent Medical Education Congress.
Marketing in the Post-Vioxx Era
This article summarizes a panel discussion at a recent Pharmaceutical Executive Annual Marketing Summit in Philadelphia.
Thought-Leader Management: A Challenge Met
This article reviews Medigent Thought Leader, a Web-based software suite designed to dramatically improve a pharma company's communications with Key Opinion Leaders.
